Adverum Biotechnologies, Inc.
เพิ่มขึ้น

ADVM reiteration

ที่อัปเดต:
With the recent advancements about the possible change of board members and the earnings report, finally ADVM should start its climb. The first target is $3.80.
บันทึกช่วยจำ
Decrease in the short volume ratio on the stock is also a positive sign. Despite a penny increment sell wall, we are expecting the climb to resume.
บันทึกช่วยจำ
It is making its comeback. With the institutional support for the success of the company, my target price is $5.60 in the short to middle term. As soon as the issues with the Phase 2 incidence is discovered, the price will slowly regain its valued range of $15-$20.
Fundamental AnalysisSupport and Resistance

การนำเสนอที่เกี่ยวข้อง

คำจำกัดสิทธิ์ความรับผิดชอบ